Pyxis Oncology, Inc. Common Stock (PYXS) Stock Price

PYXSStock
$3.06+120.90%52W
Market Cap$255.23M
P/E
PEG Ratio
Div yield
Beta1.32

PYXS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)104.81%
Price vs S&P 500 (4W)-1.33%
VGM Score56.43

PYXS Earnings Surprise History

Q2 25-0.30est. -0.35
Q3 25-0.35est. -0.34
Q4 25-0.29est. -0.34
Q1 26-0.37est. -0.35
Q2 26-0.40est. -0.35

PYXS Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.38
4.33
4.33

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
PYXSPyxis Oncology, Inc. Common Stock
DA$3.06
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Pyxis Oncology, Inc. Common Stock

Pyxis Oncology is a preclinical-stage company developing next-generation therapeutics targeting difficult-to-treat cancers. The company's dual approach combines direct tumor cell killing with addressing underlying cancer pathologies that enable proliferation and immune evasion. This strategy aims to improve treatment outcomes for patients with limited options.